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OBJECTIVES The purpose of this study was to describe the clinical and molecular features of a large family
with maternally inherited cardiomyopathy (MICM).
BACKGROUND Recently, several mitochondrial deoxyribonucleic acid (mtDNA) point mutations have been
associated with MICM. However, the distinctive clinical and morphologic features of MICM
are not fully appreciated. This is partially due to the small size of the reported pedigrees, often
lacking detailed clinical and laboratory information.
METHODS Clinical and genetic analysis of the family was carried out.
RESULTS Echocardiography showed mostly symmetrical hypertrophic cardiomyopathy in 10 family
members. The illness had an unfavorable course. Progressive heart failure occurred in three
subjects, who eventually died; one individual underwent heart transplantation. Electrocar-
diographic or echocardiographic signs of cardiac hypertrophy in the absence of significant
clinical complaints were observed in five subjects. Neurologic examination was normal. The
mutation was detected in blood from all available subjects. Abundance of mutated molecules
ranged between 13% and 100% of total mtDNA genomes. The severity of the disease could
not be foreseen by the proportion of mutation in blood.
CONCLUSIONS This report contributes a better description of the clinical aspects of MICM and provides
important clues to distinguish it from hypertrophic cardiomyopathy. We suggest that
mtDNA mutations, particularly in the transfer ribonucleic acid for isoleucin, should be
systematically searched in patients with MICM. The identification of an underlying
maternally inherited mitochondrial DNA defect in familial cases of cardiomyopathy may
considerably influence the management and genetic counseling of affected patients. (J Am
Coll Cardiol 1999;33:1584–9) © 1999 by the American College of Cardiology
Inherited cardiomyopathies are a heterogeneous group of
disorders affecting primarily the cardiac muscle. In the last
few years, several mitochondrial deoxyribonucleic acid
(mtDNA) point mutations have been identified in patients
with cardiomyopathies (1–12). Since mtDNA is passed to
the offspring only through the mother, mtDNA-associated
disorders exhibit maternal inheritance. Therefore inherited
cardiomyopathies associated with mtDNA mutations are
collectively known as maternally inherited cardiomyopathies
(MICMs). Unfortunately, mtDNA mutations have mostly
been reported in singleton cases or small pedigrees, often
lacking detailed clinical investigation. As a consequence, the
clinical and morphologic spectrum of MICM in large
families is not yet clearly understood.
We previously reported a novel point mutation in
mtDNA, an A-to-G substitution at nucleotide position
4300, in the transfer ribonucleic acid for isoleucin (tRNAIIe)
gene, in a patient with a hypertrophic form of MICM (13).
We now describe the clinical and genetic findings of the
extended family to better define the clinical phenotype and
attempt phenotype–genotype correlations.
METHODS
Thirty-one family members (21 women, 10 men; age range:
5 to 83 years) were studied. All patients gave their informed
consent for participation in the study. Detailed clinical
history was obtained from each individual. We gave partic-
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ular attention to cardiovascular risk factors, such as hyper-
tension and coronary artery disease, as well as to clinical
features suggestive of mitochondrial disease, including ma-
trilineal history of neurological disease, diabetes, hearing
loss and skeletal muscle disease. Both cardiologic and
neurologic evaluations were carried out. The disease status
of living members was determined on the basis of history,
physical examination, 12-lead electrocardiogram and/or
two-dimensional and Doppler echocardiogram. Electrocar-
diograms were interpreted according to standard criteria
(14). Echocardiographic measurements of wall thickness
and cavity dimensions were carried out according to the
American Society of Echocardiography criteria (15). Hy-
pertrophic cardiomyopathy was defined as the echocardio-
graphic demonstration of a hypertrophied, nondilated left
ventricle in the absence of other cardiovascular or systemic
disease that could lead to left ventricular hypertrophy (16).
The extent and distribution of left ventricular hypertrophy
was evaluated in each patient. Left ventricular outflow
obstruction was diagnosed on the basis of prolonged ante-
rior mitral leaflet–septal contact or the presence of pressure
gradient $30 mm Hg at Doppler examination (17). End-
stage dilation in hypertrophic cardiomyopathy (HCM) was
interpreted as a disease status characterized by cavity en-
largement with impaired systolic function and/or left ven-
tricular wall thinning, as the result of serial assessments (18).
Deceased family members were considered affected on the
basis of clinical records showing a history of progressive
heart disease and cardiac death. Heart and skeletal muscle
samples were obtained from the proband (IV-01). Histo-
logic stains were carried out with hematoxylin–eosin and
Masson trichrome on paraffin sections; a modified Gomori
trichrome stain was performed on frozen sections according
to standard methodologies.
Genetic analysis. Total genomic DNA was extracted from
peripheral leukocytes of all available family members and
from transplanted heart and skeletal muscle of the proband
(IV-01). A combined polymerase chain reaction (PCR)–
restriction fragment length polymorphism analysis was used
to detect the A4300G mutation. The following primers
were used for PCR amplification of the mtDNA region
encompassing the tRNAIIe gene: a mismatch sense primer
(59-39) 4281-4298 AGAGTTACTTTGATAGGG (un-
derlined nucleotide is mismatch), and a reverse primer
(59-39) 4544-4523, according to the published Cambridge
sequence (19). In combination with the A4300G mutation,
the mismatch creates a new restriction site for the endonu-
clease HphI (GGTGAN8/N7). A last “hot-PCR” cycle was
performed as described. Polymerase chain reaction products
were digested overnight with HphI and electrophoresed
through a 12% nondenaturing polyacrylamide gel. Contrary
to wild-type molecules, the 263-bp PCR-amplified frag-
ments carrying the mutations are cleaved into two fragments
of 235 and 28 base pairs, respectively. The relative abun-
dance of the mutant genomes was quantitated using a
Phosphorimager (Biorad, Hercules, California).
RESULTS
Clinical, electrocardiographic, echocardiographic and ge-
netic data of the 31 family members are listed in Table 1.
From a cardiologic standpoint, 13 family members were
affected by cardiomyopathy. Diagnosis was based on the
echocardiographic examination in 10 individuals (including
the proband), and a history of progressive heart disease and
cardiac death in three deceased members (II-07, III-02,
III-16). In five cases (III-01, III-03, III-04, III-05, III-23)
electrocardiography was abnormal, but echocardiography
was not available. Thus, cardiomyopathy was considered
only suspected.
Clinical Profile
Proband. The proband (IV-01), a 37-year-old man, was
referred at age 34 years for heart transplantation. His
complaints of exertional dyspnea dated back to his early 20s.
At that time nonobstructive hypertrophic cardiomyopathy
had been diagnosed by means of echocardiography (Table
2). The patient had been treated with beta-adrenergic
blocking agents and remained mildly symptomatic for the
following 7 years. Thereafter, symptoms progressively wors-
ened and the patient developed congestive heart failure;
ventricular dilation was diagnosed and digoxin and vasodi-
lators were added to therapy. Notwithstanding, the patient
entered New York Heart Association class IV. On first
examination, the electrocardiogram showed sinus rhythm,
with extreme QRS left axial deviation, and deep Q waves in
leads I, aVL and V6. The echocardiogram showed a
hypertrophied left ventricle with cavity dilation and a
depressed systolic function (Fig. 1). At the age of 34 years,
he underwent heart transplantation. He is alive and in good
health condition three years after surgery. Gross examina-
tion of the explanted heart showed left ventricular hyper-
trophy with mild dilation of the trabecular portion. Histo-
logic examination revealed severe myocyte hypertrophy with
diffuse sarcoplasmic vacuolization and mild interstitial fi-
brosis. Myofiber disarray was only focal and inconspicuous
(,5%) on multiple ventricular samplings. No vascular
changes were observed. Histologic examination of skeletal
muscle showed ragged-red fibers, a hallmark of mitochon-
drial dysfunction. This prompted us to carry out mtDNA
analysis, which eventually led us to identify a novel mtDNA
mutation (13).
Abbreviations and Acronyms
HCM 5 hypertrophic cardiomyopathy
MICM 5 maternally inherited cardiomyopathy
mtDNA 5 mitochondrial deoxyribonucleic acid
PCR 5 polymerase chain reaction
tRNAIIe 5 transfer ribonucleic acid for isoleucin
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Family members. Family history revealed many relatives
suffering from “cardiac disease.” An extensive survey dis-
closed 12 affected and 5 suspected individuals on the
maternal side of the family (Table 1, Fig. 2).
Reportedly, three family members (II-07, III-02, III-16)
had died of cardiac death at the age of 41, 54 and 33 years,
respectively. Available clinical information confirmed the
diagnosis of cardiac disease, with onset in early adult life and
a progressive course leading to refractory heart failure,
similar to that observed in the proband. Of the nine living
affected members, two (IV-03, IV-09) complained of dys-
pnea on exertion, one (IV-05) of chest pain and one of both
(III-15); the others (III-13, IV-08, IV-20, IV-23, V-14)
were asymptomatic. In two symptomatic patients beta-
blocker therapy was started with some benefits. None of the
family members had a history of systemic hypertension or
blood pressure higher than 140/90 mm Hg at rest or other
causes of myocardial hypertrophy.
The clinical profile of the five subjects with cardiomyop-
athy suspected on the basis of electrocardiographic abnor-
malities was characterized by dyspnea on exertion in two
cases (III-03, III-05) and absence of cardiac symptoms in
three (III-01, III-04, III-23).
Neurologic examination was normal in all living subjects.
In particular, no signs of skeletal or extraocular muscle
involvement were disclosed.
Cardiac Findings
Echocardiographic features of the 10 affected members are
reported in Table 2. Ten individuals showed a hypertrophic
form of cardiomyopathy. In nine, both the left ventricular
septum and the free wall, including the posterior wall (Fig.
3), were involved. None had complete systolic anterior
motion of the mitral valve or evidence of left ventricular
gradient on Doppler ultrasonography. Nine patients with
HMC had abnormal electrocardiograms with a pattern of










II-01 83/F None Normal n.a. 62
II-07 41/F CD n.a. n.a. n.a.
III-01 56/F None T n.a. 88
III-02 54/F CD n.a. n.a. n.a.
III-03 54/F Dyspnea LVH,T n.a. 95
III-04 51/F None T n.a. 40
III-05 56/M Dyspnea LVH,T n.a. 82
III-13 45/F None Normal LVH 100
III-14 43/F None Normal n.a. 100
III-15 42/F Dyspnea, CP LVH,T LVH 92
III-16 33/F CD n.a. n.a. n.a.
III-23 44/M LC LVH n.a. n.a.
IV-01 37/M NYHA IV LVH LVH and dilation 95
99(H) 99(M)
IV-02 29/F None Normal Normal 87
IV-03 36/F Dyspnea LVH,T, short
PR interval
LVH 95
IV-05 33/M CP LVH LVH n.a.
IV-07 23/F None Normal Normal 92
IV-08 19/M None LVH LVH n.a.
IV-09 28/F Dyspnea LVH,T LVH 13
IV-20 25/M None LVH,T LVH 76
IV-22 24/F None Normal Normal 94
IV-23 23/M None LVH LVH 100
IV-24 24/F None Normal n.a. 90
IV-25 25/F None Normal Normal 93
IV-26 16/F None Normal Normal 95
IV-27 20/M None Normal n.a. n.a.
V-01 10/M None Normal n.a. n.a.
V-02 5/M None Normal n.a. n.a.
V-05 10/F None Normal Normal 88
V-06 12/F None Normal Normal 93
V-14 7/F None LVH LVH n.a.
2D 5 two-dimensional; CD 5 cardiac death; CP 5 chest pain; ECG 5 electrocardiogram; H 5 heart; LC 5 lung cancer;
LVH 5 left ventricular hypertrophy; M 5 muscle; mtDNA 5 mitochondrial deoxyribonucleic acid; n.a. 5 not available;
NYHA 5 New York Heart Association; T 5 T wave inversion.
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left ventricular hypertrophy and T wave inversion; in one
case (IV-03) a short PR interval (0.10 ms) was also
measured. The remaining patient with HCM on echocar-
diographic examination had a normal electrocardiogram. In
five cases (III-01, III-03, III-04, III-05, III-23) HCM was
suspected based on the electrocardiographic pattern of left
ventricular hypertrophy (voltage criteria) and strain or T
wave inversion in $2 leads.
Genetic Analysis
The presence and relative abundance of the A4300G
mutation was investigated in peripheral leukocytes from 21
available family members. The results are reported in Table
1. Coexistence of mutated and wild-type mtDNA genomes
(heteroplasmy) was detected in all but three subjects (III-13,
III-14, IV-23), with mutated mtDNAs in blood ranging
widely between 13% and 95%. Since no patient had overt
skeletal myopathy requiring muscle biopsy and endomyo-
cardial biopsy was not indicated, the abundance of mutated
mtDNAs in tissues other than blood could be assessed only
in the proband (IV-01). Very high percentages were found
in all tissues, although they were slightly higher in the heart
and skeletal muscle than in blood.
DISCUSSION
More than 50 different mtDNA point mutations have been
associated with a wide variety of human diseases (20). These
disorders are clinically, histologically and biochemically
diverse, but they all preferentially affect tissues with high
metabolic requirements such as brain, skeletal muscle and
the heart. The latter is often affected in the frame of a
multisystem disorder. As an example, about 20% of patients
with the syndrome of mitochondrial encephalomyopathy
with lactic acidosis and stroke-like episodes have a cardio-
myopathy, mostly hypertrophic (21). On the other hand,
mtDNA mutations have been reported in patients with
cardiomyopathy as the sole or dominant clinical feature, a
condition known as MICM (13). However, the clinical
description of MICM is often incomplete. Its specific
features are poorly recognized and it is unclear how it can be
differentiated from other forms of familial cardiomyopathy.
Our observations in a large family with MICM provide the
opportunity of further defining the clinical and laboratory
characteristics of this disease and comparing it to other well
defined forms of inherited cardiomyopathy such as HCM.
Clinical features of the affected members. All affected
members were found to be maternally related over five
generations. Despite the considerable number of family
members, no case of male-to-male transmission was ob-
served. On the other hand, only mothers, either affected or
healthy, transmitted the disease to their male and female
Figure 1. M-mode and two-dimensional echocardiogram of the
proband showing left ventricular wall hypertrophy, left ventricular
dilation and diffuse hypokinesis.
















III-13 45/F 13 12 38 25 32
III-15 42/F 22 16 49 36 33
IV-01 20/M 17 13 47 30 n.a.
34 18 11 69 60 37
IV-03 36/F 14 15 48 32 18
IV-05 32/M 18 23 47 33 30
IV-08 19/M 27 25 45 25 37
IV-09 28/F 17 18 40 26 31
IV-20 25/M 18 17 49 32 33
IV-23 23/M 13 16 46 30 46
V-14 7/F 12 15 45 32 31
2D 5 two-dimensional; LA 5 left atrium; LVEDD 5 left ventricular end-diastolic diameter; LVESD 5 left ventricular
end-systolic diameter; LVWT 5 left ventricular wall thickness; n.a. 5 not available; PW 5 posterior wall; VS 5 ventricular
septum.
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offspring. These data on the extended pedigree strongly
support a maternal mode of inheritance.
Cardiac findings. All affected patients presented with a
pure hypertrophic form of cardiomyopathy without symp-
toms of other system dysfunction, including the central
nervous system.
Echocardiography disclosed left ventricular hypertrophy,
without outflow obstruction, in all affected members. Left
ventricular hypertrophy was more often symmetrical than
asymmetrical; moreover, almost all patients showed an
increased wall thickening of the posterior wall, which was
clearly predominant in two cases (IV-05, IV-23). In HCM,
left ventricular hypertrophy is characteristically asymmetric;
a concentric hypertrophic pattern accounts for only 1% of
the cases (22). The anterior ventricular septum is the
predominant region of hypertrophy in the majority of cases
(83%); hypertrophy mainly involving the left ventricular
posterior wall is rare (2%). In addition, significant myofiber
disarray, which is the histologic hallmark of HCM, was not
observed. In the proband, serial echocardiograms demon-
strated an evolution from a hypertrophied, nondilated left
ventricle to left ventricular cavity enlargement and impaired
systolic function, which is considered rare in HCM (18).
The illness often had an adverse clinical course, with
three deceased members (II-07, III-02, III-16), and a
fourth individual received a transplant (IV-01). Only five
subjects (III-13, IV-08, IV-20, IV-23, V-14) showed elec-
trocardiographic or echocardiographic signs of hypertrophy,
while asymptomatic. Notably V-14 is a seven-year-old girl.
These findings suggest a more severe form than HCM with
a relatively common rapidly progressive course. Interest-
ingly, neither atrial fibrillation nor sudden death were
relevant features. Whether this clinical presentation is re-
lated to this specific mtDNA mutation or represents a
common feature of MICM remains to be established. The
latter hypothesis seems to be supported by other reports
(2,4,6,8,12); however, more clinical and follow-up observa-
tions are needed.
Genotype-phenotype correlations. All studied subjects
harbored the A4300G mutation in the tRNAIIe gene.
However, no obvious correlation was found between disease
status or severity and abundance of mutated genomes in
peripheral leukocytes. In fact, a very high proportion
(.95%) of mutated mtDNAs was found both in affected
members (IV-01, IV-23) and healthy subjects (IV-26). This
lack of correlation is not infrequent in other disorders
associated with mtDNA mutations (23). Possible explana-
tions include the widely variable degree of heteroplasmy as
well as differences in the threshold for clinical expression
among different tissues. Moreover, the fate and expression
of a given mtDNA mutation in different cultured tissues
appear to be strongly influenced by tissue-specific factors
encoded in the nucleus, which could be different even within
the same family (24).
Conclusions. The true frequency of MICM within the
familial forms of cardiomyopathy has not been clearly
established. Because many cardiologists are relatively unfa-
miliar with mitochondrial disorders, a matrilinear lineage of
cardiomyopathy may be confused with an autosomal dom-
inant one. We suggest that mtDNA analysis be included in
the working-up of familial as well as sporadic cases of
Figure 2. Family tree. Arrowhead indicates the proband. Filled symbols represent affected individuals.
Figure 3. M-mode echocardiogram of an affected family member
showing symmetrical left ventricular wall hypertrophy with normal
diastolic and systolic diameters.
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HCM, especially when hypertrophy is symmetrical or when
the family history is compatible with maternal inheritance.
The tRNAIIe gene is probably a mutational “hot spot” for
MICM and should be preferentially studied (1,6,12,13).
Our original description of the A4300G mutation was,
indeed, the successful result of such an approach in a series
of familial cases of unexplained HCM. The same strategy
has recently yielded the identification of two novel muta-
tions in the tRNAIIe gene (24).
From a more practical point of view, it should be kept in
mind that detecting mtDNA mutations associated with
cardiomyopathy in a given family might have considerable
impact on management and genetic counseling. The off-
spring of male patients can be safely excluded as potential
affected subjects, whereas all the children of an affected
mother should be considered at risk.
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